$65.88 Million in Sales Expected for Health Catalyst, Inc. (NASDAQ:HCAT) This Quarter

Analysts expect Health Catalyst, Inc. (NASDAQ:HCATGet Rating) to report $65.88 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for Health Catalyst’s earnings, with the lowest sales estimate coming in at $65.11 million and the highest estimate coming in at $66.77 million. Health Catalyst posted sales of $55.85 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 18%. The firm is expected to report its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Health Catalyst will report full year sales of $290.59 million for the current fiscal year, with estimates ranging from $290.00 million to $291.49 million. For the next year, analysts expect that the business will post sales of $348.69 million, with estimates ranging from $344.68 million to $352.12 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Health Catalyst.

Health Catalyst (NASDAQ:HCATGet Rating) last announced its quarterly earnings results on Tuesday, March 1st. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.07. The company had revenue of $64.72 million during the quarter, compared to analyst estimates of $63.17 million. Health Catalyst had a negative return on equity of 21.30% and a negative net margin of 63.33%. The firm’s revenue was up 21.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.41) earnings per share.

HCAT has been the subject of a number of recent research reports. SVB Leerink lowered their target price on Health Catalyst from $64.00 to $48.00 and set an “outperform” rating for the company in a research note on Wednesday, March 2nd. The Goldman Sachs Group initiated coverage on Health Catalyst in a research note on Friday, February 11th. They issued a “buy” rating and a $48.00 target price for the company. BTIG Research lowered their target price on Health Catalyst from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Friday, March 25th. Raymond James lowered their target price on Health Catalyst from $70.00 to $40.00 and set a “strong-buy” rating for the company in a research note on Friday, March 4th. Finally, Canaccord Genuity Group lowered their target price on Health Catalyst from $62.00 to $35.00 in a research note on Wednesday, March 2nd. Twelve equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $42.43.

HCAT stock opened at $14.69 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.46 and a current ratio of 5.46. Health Catalyst has a 1 year low of $14.30 and a 1 year high of $59.50. The firm has a market cap of $792.33 million, a P/E ratio of -4.58 and a beta of 1.18. The stock has a 50-day simple moving average of $23.05 and a 200-day simple moving average of $33.15.

In other Health Catalyst news, General Counsel Daniel H. Orenstein sold 4,112 shares of the stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $26.82, for a total transaction of $110,283.84. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Paul Horstmeier sold 10,750 shares of the stock in a transaction that occurred on Monday, February 7th. The stock was sold at an average price of $29.10, for a total value of $312,825.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,036 shares of company stock worth $1,247,804. 2.00% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in HCAT. Commonwealth Equity Services LLC lifted its holdings in shares of Health Catalyst by 9.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,710 shares of the company’s stock worth $535,000 after purchasing an additional 888 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Health Catalyst by 5.5% in the 3rd quarter. Amalgamated Bank now owns 8,910 shares of the company’s stock worth $446,000 after purchasing an additional 467 shares during the last quarter. Raymond James & Associates lifted its holdings in shares of Health Catalyst by 7.6% in the 3rd quarter. Raymond James & Associates now owns 119,002 shares of the company’s stock worth $5,951,000 after purchasing an additional 8,387 shares during the last quarter. Advisor Group Holdings Inc. lifted its holdings in shares of Health Catalyst by 27.3% in the 3rd quarter. Advisor Group Holdings Inc. now owns 1,466 shares of the company’s stock worth $73,000 after purchasing an additional 314 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Health Catalyst by 1.5% in the 3rd quarter. Swiss National Bank now owns 83,700 shares of the company’s stock worth $4,186,000 after purchasing an additional 1,200 shares during the last quarter. 97.53% of the stock is currently owned by institutional investors.

Health Catalyst Company Profile (Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.

Featured Articles

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.